



## **NOXXON Receives Research Grant from the Federal Ministry of Education and Research**

Berlin, Germany April 7, 2008: NOXXON announced today that the company was awarded a research grant from Germany's Federal Ministry of Education and Research (BMBF). NOXXON will receive approximately one million Euro in research funding under the BioChancePlus initiative, a program that supports innovative research in biotechnology companies. The program is dedicated to further strengthen and broaden NOXXON's drug discovery platform to identify innovative medicines based on mirror-image oligonucleotides (Spiegelmers®). NOXXON's Chief Scientific Officer Dr. Sven Klussmann commented: "We are delighted that the government has decided to reward NOXXON's excellent research. The funding will be beneficial in supporting the development and growth of existing and new technologies."

### **About NOXXON Pharma AG:**

Based on one of the biggest and best protected patent portfolios in the industry, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) are highly specific for the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website info: <http://www.noxxon.net>

General contact: Emmanuelle Delabre  
NOXXON Pharma AG  
Max-Dohrn-Strasse 8-10  
10589 Berlin, Germany  
Phone: + 49 30 72 62 47 0  
FAX: + 49 30 72 62 47 225  
Email: [edelabre@noxxon.net](mailto:edelabre@noxxon.net)